CITY OF INDUSTRY, Calif.
- Nov. 8, 2018
-- Small Incision Lenticule Extraction (SMILE (http://www.iqlaservision.com/
smile/)) has been gaining popularity around the globe as the latest treatment for nearsightedness (myopia). Now, following its recent introduction to the United States and the Oct. 5 FDA premarket approval as a treatment for astigmatism, SMILE is giving patients more options than ever to address their vision challenges.
Unlike other refractive surgeries, SMILE uses only one laser rather than two to make a small incision in the eye. This single-step corrective method minimizes the chance of post-surgery dry eyes for patients who struggle with that condition and promotes even faster healing than its corrective counterparts.
Astigmatism, a condition affecting one in three Americans (https://www.aao.org/
(American Academy of Ophthalmology)
, is caused by a spherically-
shaped cornea or lens that results in distorted or blurred vision. It is often found in conjunction with nearsightedness or farsightedness. Refractive surgeries, such as LASIK, have been used to treat astigmatism for many years. But the new minimally invasive SMILE procedure has generated a global buzz among patients and surgeons alike.
Said Dr. Robert T. Lin (http://www.iqlaservision.com/blog/an-interview-with-dr-ro...
), founder and refractive surgeon at IQ Laser Vision, "SMILE paves the way for more people than ever to experience their best vision. And as we gear up to extend this service to more of our patients across all our California locations (http://www.iqlaservision.com/locations/
), that's something we're definitely excited about."
Approximately 1.5 million SMILE procedures have been performed in more than 70 countries over the last decade. With more than 1700 surgeons already using it to help their patients see better, the FDA approval holds the key to a brighter future for both patients and ophthalmologists alike.